Free Trial
NASDAQ:SLGL

Sol-Gel Technologies Q2 2023 Earnings Report

Sol-Gel Technologies logo
$7.51 -0.08 (-1.05%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sol-Gel Technologies EPS Results

Actual EPS
-$2.20
Consensus EPS
-$2.60
Beat/Miss
Beat by +$0.40
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
$1.55 million
Beat/Miss
Missed by -$960.00 thousand
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Thursday, August 10, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Sol-Gel Technologies' Q4 2024 earnings is scheduled for Thursday, August 14, 2025

Earnings Documents

Sol-Gel Technologies Earnings Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Sol-Gel Reports First Quarter 2025 Results
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL), together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

View Sol-Gel Technologies Profile

More Earnings Resources from MarketBeat